Antioxidant therapeutic - Zambon
Latest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator Zambon SpA
- Class
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Respiratory tract disorders
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for preclinical development in Respiratory-tract-disorders in Italy
- 27 Oct 2020 Antioxidant therapeutic - Zambon is available for licensing as of 27 Oct 2020. https://www.zambon.com/en/innovation/partnering
- 27 Oct 2020 Preclinical trials in Respiratory tract disorders in Italy (unspecified route) (Zambon pipeline, October 2020)